These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 37678423)

  • 1. Letter to the Editor: Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection.
    Ahmed M; Abbas J; Imtiaz H
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102067. PubMed ID: 37678423
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
    Beavers CJ
    Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems.
    Patrono C; Volpe M
    Eur Heart J; 2021 Jan; 42(1):14-15. PubMed ID: 33428718
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
    Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
    Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?
    Georgianos PI; Eleftheriadis T; Liakopoulos V
    Eur J Clin Invest; 2023 Feb; 53(2):e13864. PubMed ID: 36038512
    [No Abstract]   [Full Text] [Related]  

  • 11. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection.
    Parfianowicz D; Shah S; Nguyen C; Maitz TN; Hajra A; Goel A; Sreenivasan J; Aronow WS; Vyas A; Gupta R
    Curr Probl Cardiol; 2022 Dec; 47(12):101386. PubMed ID: 36057315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease].
    Liu WY; Yu SQ
    Sheng Li Xue Bao; 2022 Dec; 74(6):1023-1030. PubMed ID: 36594390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finerenone (Kerendia) for chronic kidney disease.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):131-132. PubMed ID: 34544101
    [No Abstract]   [Full Text] [Related]  

  • 16. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
    Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
    Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
    Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
    Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.